NON RARE IN EUROPE: Ankylosing spondylitis Advocacy Hub | UniteRare

At a Glance

Live from database

💊

4FDA treatments

💰

3Open funds

Regulatory Watchboard

No FDA or trial events recorded yet for NON RARE IN EUROPE: Ankylosing spondylitis.

Financial Assistance

3 programs

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs3

Rinvoq

AbbVie, Inc.

OpenContact for detailsApply ↗

HUMIRA

AbbVie, Inc.

OpenContact for detailsApply ↗

SIMPONI ARIAï¿½

Janssen Research & Development, LLC

OpenContact for details

View all support programs on disease page →

Approved Treatments

4 FDA-approved

HUMIRA

(adalimumab)Orphan drugstandard

AbbVie, Inc.

12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalim...

FDA label ↗

Enbrel

(etanercept)Orphan drugstandard

Immunex Corporation

Tumor Necrosis Factor Blocker [EPC]

12.1 Mechanism of Action TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important rol...

FDA label ↗

SIMPONI ARIAï¿½

(golimumab)Orphan drugstandard

Janssen Research & Development, LLC

Tumor Necrosis Factor Blocker [EPC]

12.1 Mechanism of Action Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα. This...

FDA label ↗

Remicade

(infliximab)Orphan drugstandard

Janssen Biotech, Inc.

Tumor Necrosis Factor Blocker [EPC]

12.1 Mechanism of Action Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms o...

FDA label ↗

View full treatment details on disease page →